Antibody Ingredients TRIZ Cases

Dual checkpoint inhibition with anti-PD-1 and anti-CD27 antibodies improves survival outcomes while maintaining a favorable safety profile.

Antibodies targeting MICA alpha3 domains reduce soluble protein levels, enhancing NK cell cytotoxicity against tumor cells.

Anti-gabapentin antibody replaces chromatography to resolve precision and throughput trade-offs.

Histidine protonation enables acidic pH-selective antibody binding to VISTA, improving intratumoral specificity and pharmacokinetics.

A humanized anti-theophylline antibody binds the target molecule with high affinity using specific amino acid sequences.

Non-peptide linkers expand chemical space in antibody-drug conjugates, resolving peptide diversity limits.

IL-4R inhibitor neutralizes IL-4 and IL-13 to control atopic dermatitis without corticosteroid-induced skin atrophy.

Antibodies targeting BCMA block BAFF and APRIL signals, resolving incomplete remission and side effects in multiple myeloma treatment.

Anti-HER3 antibodies bind the extracellular domain of HER3 to reduce signal transduction in cancers where anti-HER2 therapies fail.

Recombinant humanized antibodies eliminate immune reactions and health risks associated with biological extracts while maintaining therapeutic efficacy.

Liquid anti-CD200 antibody formulations use surfactants and buffers to prevent aggregation during refrigerated storage.

Using resistant tumor homogenates overcomes the limitation of known antigens, generating antibodies that specifically target resistance-associated epitopes.

Antibodies neutralize soluble human CD39 enzymatic activity, reducing immunosuppression by decreasing adenosine levels in the tumor microenvironment.

An anti-CLDN18.2 antibody-drug conjugate delivers cytotoxic payloads to tumor cells via a specific linker mechanism.

Multispecific antibodies bind GPC3 and CD137 to localize immune activation, reducing liver toxicity while maintaining efficacy.

Neutralizing antibodies target hyperglycosylated hCG to inhibit cancer metastasis while preventing unwanted pregnancy.

Multispecific antigen-binding molecule recruits T cells via CD3 and CD137 binding to induce cancer cell lysis.

Low CD45 expression predicts effective CD26 antibody treatment, resolving low clinical activity.

Optimized CDR sequences enable selective recognition of CLDN18.2 without cross-reactivity to CLDN18.1.

Antibodies disrupt NELL2-Robo3 signaling to reduce tumor growth while preventing heart and lung damage from chemotherapy.

Anti-CD277 antibodies overcome immunosuppressive mechanisms in cancer by targeting CD277 on dendritic cells to boost T cell activation potency.

Optimized complementarity determining regions enable sustained Tim-3 internalization, resolving inadequate immune suppression modulation in cancer therapies.

Chelated metal complexes linked to IGF-1R antibodies concentrate radiation at tumor sites, reducing normal tissue toxicity and enabling higher cumulative doses.

Modifying amino acid sequences in the variable regions yields a dissociation constant of 1.0 × 10^-10 M or less, enabling tumor growth inhibition at low doses.

Antibodies bind Sonic Hedgehog polypeptides to overcome chemotherapy resistance in non-small cell lung cancer.

Segmenting CD3 binding into spatially separated domains prevents uncontrolled cytokine release while maintaining specific tumor targeting.

SEZ6 modulators target cancer stem cells to prevent recurrence and metastasis in platinum-resistant malignancies.

Anti-ALK1 antibodies bind endothelial receptors to block LDL transcytosis, reducing plaque formation without inhibiting BMP9 signaling.

Segmented antibody complexes use protease cleavage to restrict T-cell activation to the tumor site, preventing systemic cytokine release syndrome.

Smaller segmented polypeptides penetrate tumors better than large antibodies, reducing dosing and side effects.

Bispecific antibodies merge catalytic site and LRP1 binding domains into one molecule, blocking dual functions without requiring combination therapy.

Agonist anti-MET antibodies activate HGF-MET signaling to reduce tumor burden and fibrosis while preserving quality of life.

Site-specific non-natural amino acid residues anchor antibody conjugation, eliminating heterogeneity and low yields from random attachment sites.

Antibodies targeting the Tim-3 IgV domain block immune suppression, restoring IFN-gamma production and enhancing cancer therapy efficacy.

Modified CDR sequences in humanized monoclonal antibodies overcome resistance mechanisms by blocking neuregulin binding to HER3 receptors.

An antibody binds lymphocyte activation gene-3 to modulate T cell activity and enhance immune responses.

A monoclonal antibody targets cell surface vimentin to detect circulating tumor cells.

Anti-PD-L1 monoclonal antibodies enhance T-cell activation by blocking immunosuppressive signals to improve cancer treatment outcomes.

A biomarker panel measures chemokine and cytokine levels to predict immune-related adverse events before immunotherapy initiation.

Synthetic nanocarriers generate humoral and cytotoxic T lymphocyte immune responses without saponin-cholesterol adjuvants, reducing off-target toxicity.

Selective A2AR agonists inhibit natural killer T cell activation, decreasing IFN-gamma production and neutrophil accumulation during reperfusion.

Non-blocking PD-1 antibodies rescue exhausted T-cells to control disease while avoiding immune suppression.

A PV1 peptide composition binds MHC Class I molecules to stimulate antigen-specific T cells.